M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

NCT06177041 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

486

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced Unresectable or Metastatic Gastric Cancer
Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions

DRUG: M108 monoclonal antibody
DRUG: Placebo
DRUG: Oxaliplatin
DRUG: Capecitabine

Sponsor

FutureGen Biopharmaceutical (Beijing) Co., Ltd